By downregulating the antitumor genes tensin homology protein (PTEN) and cyclin-dependent kinase inhibitor 1 (CDKN1A), miR-93 can promote cell proliferation, migration, and invasion by activating the c-Met/PI3K/Akt signaling pathway; additionally, anti-miR-93 transfection makes HCC cells more sensitive to sorafenib and tivantinib treatment [40]. Here, MET is linked to hepatocellular carcinoma.